MCID: VLV011
MIFTS: 48

Vulvovaginal Candidiasis malady

Categories: Infectious diseases, Skin diseases, Reproductive diseases

Aliases & Classifications for Vulvovaginal Candidiasis

Aliases & Descriptions for Vulvovaginal Candidiasis:

Name: Vulvovaginal Candidiasis 12 3 14
Candidiasis, Vulvovaginal 42 69
Candidiasis of Vulva and Vagina 12
Candidal Vulvovaginitis Nos 12
Candidiasis Vulvovaginal 52
Candidal Vulvovaginitis 12
Monilial Vulvovaginitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2272
ICD10 33 B37.3
ICD9CM 35 112.1
MeSH 42 D002181
NCIt 47 C2914
UMLS 69 C0700345

Summaries for Vulvovaginal Candidiasis

CDC : 3 Genital / vulvovaginal candidiasis (VVC) is also sometimes called a "yeast infection," and it occurs when there is overgrowth of the normal yeast in the vagina. This infection is relatively common -- nearly 75% of all adult women have had at least one "yeast infection" in their lifetime.

MalaCards based summary : Vulvovaginal Candidiasis, also known as candidiasis, vulvovaginal, is related to vulvar vestibulitis syndrome and candidiasis. An important gene associated with Vulvovaginal Candidiasis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and Folate Metabolism. The drugs Clotrimazole and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and colon, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Disease Ontology : 12 A candidiasis that involves fungal infection of the vaginal mucous membranes in women caused by Candida albicans. The symptoms include intense vulval pruritus, burning, erythema and dyspareunia associated with a creamy white, curd-like discharge.

Related Diseases for Vulvovaginal Candidiasis

Diseases related to Vulvovaginal Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
id Related Disease Score Top Affiliating Genes
1 vulvar vestibulitis syndrome 29.8 IL2 IL4
2 candidiasis 11.1
3 vulvovaginitis 11.1
4 vaginitis 10.6
5 indomethacin antenatal infection 10.3 CD79A MBL2
6 bacterial vaginosis 10.3
7 gonococcal synovitis 10.3 CLEC7A MBL2
8 good syndrome 10.2 CD79A MBL2
9 hemangioma of orbit 10.2 CD79A IL2
10 fallopian tube carcinoma 10.2 CD79A IL2
11 basilar artery occlusion 10.2 CD79A DEFB4A
12 plantar wart 10.2 CD79A IL2
13 waldeyer's ring cancer 10.2 CLEC7A DEFB4A
14 ectothrix infectious disease 10.2 CD79A CLEC7A MBL2
15 diabetic angiopathy 10.2 CD79A IL4
16 bowman's membrane folds or rupture 10.2 DEFB1 DEFB4A
17 alkhurma hemorrhagic fever 10.1 CD79A IL4
18 cutaneous sclerosis 10.1 IL1RN NLRP3
19 neonatal antiphospholipid syndrome 10.1 DEFB1 DEFB4A
20 polyneuropathy due to drug 10.1 CD79A IL4
21 cutaneous ganglioneuroma 10.1 CD79A IL4
22 egg allergy 10.1 IL1RN NLRP3
23 hypoparathyroidism, x-linked 10.1 CD79A IL4
24 mycoplasmal pneumonia 10.1 CLEC7A NLRP3
25 ectropion 10.1 CLEC7A IL4
26 dextrocardia 10.1 CD79A IL1RN
27 isthmus cancer 10.1 CD79A IL4
28 sarcoma 10.1 IL2 IL4
29 autosomal dominant deafness-onychodystrophy syndrome 10.1 IL2 IL4
30 barbiturate dependence 10.1 CD79A DEFB4A IL2
31 candida glabrata 10.1
32 thelaziasis 10.1 IL2 IL4
33 sparganosis 10.1 CD79A IL4
34 osteodysplasty precocious of danks mayne and kozlowski 10.1 CD79A IL4
35 multiple epiphyseal dysplasia due to collagen 9 anomaly 10.1 IL2 IL4
36 apricot allergy 10.1 CD79A IL4
37 porokeratosis 3, disseminated superficial actinic 10.1 IL1RN NLRP3
38 stomatitis 10.1 IL1RN IL2
39 mental retardation hypotonia skin hyperpigmentation 10.1 IL1RN MBL2
40 cutaneous fibrous histiocytoma 10.1 DEFB4A IL4
41 congenital hypothyroidism 10.1 CLEC7A IL4
42 inclusion conjunctivitis 10.1 CD79A IL1RN IL2
43 newcastle disease 10.1 CD79A IL1RN IL2
44 warthin tumor 10.1 IL1RN MBL2 NLRP3
45 motor peripheral neuropathy 10.0 CD79A CLEC7A IL4
46 mental retardation, autosomal dominant 22 10.0 IL1RN NLRP3
47 venezuelan hemorrhagic fever 10.0 CD79A IL2
48 chronic gonorrhea of cervix 10.0 CD79A CLEC7A DEFB4A MBL2
49 intracranial hemorrhage in brain cerebrovascular malformations 10.0 CD79A IL1RN NLRP3
50 clostridium difficile colitis 10.0 CD79A IL2 IL4

Comorbidity relations with Vulvovaginal Candidiasis via Phenotypic Disease Network (PDN): (show all 12)


Acute Cystitis Anxiety Disorder
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Oral Candidiasis
Osteoporosis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Vulvovaginal Candidiasis:



Diseases related to Vulvovaginal Candidiasis

Symptoms & Phenotypes for Vulvovaginal Candidiasis

GenomeRNAi Phenotypes related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.75 DEFB1 CLEC7A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.75 CLEC7A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.75 IL1RN
4 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.75 CLEC7A
5 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.75 CLEC7A
6 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.75 IL1RN
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.75 CLEC7A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.75 CLEC7A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.75 CLEC7A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.75 CLEC7A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.75 CLEC7A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.75 CLEC7A DEFB1 IL1RN
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.75 CLEC7A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.75 CLEC7A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.75 CLEC7A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.75 CLEC7A
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.75 CLEC7A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.75 CLEC7A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.75 CLEC7A IL1RN
20 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.75 CLEC7A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.75 CLEC7A DEFB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.75 CLEC7A
23 Increased shRNA abundance GR00327-A 9.26 CD79A DEFB1 IL1RN IL4

MGI Mouse Phenotypes related to Vulvovaginal Candidiasis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.76 CD79A CLEC7A F2 IL1RN IL2 IL4
2 digestive/alimentary MP:0005381 9.65 CLEC7A F2 IL2 IL4 NLRP3
3 homeostasis/metabolism MP:0005376 9.56 CD79A CLEC7A F2 IL1RN IL2 IL4
4 immune system MP:0005387 9.23 IL1RN IL2 IL4 MBL2 NLRP3 CD79A

Drugs & Therapeutics for Vulvovaginal Candidiasis

Drugs for Vulvovaginal Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 23593-75-1 2812
2
Fluconazole Approved Phase 4,Phase 3,Phase 2,Early Phase 1 86386-73-4 3365
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 22916-47-8 4189
4 Dequalinium Approved Phase 4 6707-58-0
5
Terconazole Approved Phase 4,Early Phase 1 67915-31-5 441383
6 Antifungal Agents Phase 4,Phase 3,Phase 2,Early Phase 1
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Early Phase 1
8 Anti-Infective Agents, Local Phase 4,Phase 3
9 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
10 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
11 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
12 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
14 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
15 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
16
Clindamycin Approved, Vet_approved Phase 3,Early Phase 1 18323-44-9 29029
17
Amphotericin B Approved, Investigational Phase 3,Phase 2 1397-89-3 14956 5280965
18
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576 3823
19
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
20
Metronidazole Approved Phase 3,Phase 2,Early Phase 1 443-48-1 4173
21 Clindamycin palmitate Phase 3,Early Phase 1
22 Clindamycin phosphate Phase 3,Early Phase 1
23 Tetrahydrozoline Phase 3
24 Anti-Bacterial Agents Phase 3,Phase 2,Early Phase 1
25 Antiparasitic Agents Phase 3,Phase 2,Early Phase 1
26 Antiprotozoal Agents Phase 3,Phase 2,Early Phase 1
27 Liposomal amphotericin B Phase 3,Phase 2
28 Secnidazole Phase 3
29
Aluminum hydroxide Approved Phase 1, Phase 2 21645-51-2
30 Titanium dioxide Approved Phase 2 13463-67-7
31 Adjuvants, Immunologic Phase 1, Phase 2
32 Antacids Phase 1, Phase 2
33 Anti-Ulcer Agents Phase 1, Phase 2
34 Gastrointestinal Agents Phase 1, Phase 2
35 Vaccines Phase 1, Phase 2
36 Acidophilus Nutraceutical Phase 1,Early Phase 1
37
Iron Approved 7439-89-6 23925
38
Itraconazole Approved, Investigational 84625-61-6 55283
39
Butoconazole Approved 64872-77-1, 64872-76-0 47472
40 Hydroxyitraconazole
41 Micronutrients
42 Trace Elements
43 Antibiotics, Antitubercular
44 Brewer's Yeast Nutraceutical
45 Bifidobacterium Nutraceutical

Interventional clinical trials:

(show all 46)
id Name Status NCT ID Phase
1 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4
2 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
3 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4
4 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4
5 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4
6 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3
7 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3
8 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3
9 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Completed NCT01293643 Phase 3
10 Comparative Efficacy of Ovule vs Tablet Completed NCT00755053 Phase 3
11 Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge Completed NCT02111629 Phase 3
12 ProF-001_Phase IIa Recruiting NCT03115073 Phase 2, Phase 3
13 Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis Not yet recruiting NCT02907307 Phase 3
14 Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Not yet recruiting NCT03005353 Phase 2, Phase 3
15 MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2
16 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
17 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Acute Vaginal Candidiasis (Yeast Infection) Completed NCT01891331 Phase 2
18 Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2
19 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Completed NCT01144286 Phase 2
20 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Completed NCT02733432 Phase 2
21 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2
22 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Recruiting NCT02971007 Phase 2
23 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Active, not recruiting NCT02267382 Phase 2
24 TOL-463 Phase 2 Study for Vaginitis Active, not recruiting NCT02866227 Phase 2
25 Patients With Vulvovaginal Candidiasis Not yet recruiting NCT03024502 Phase 1, Phase 2
26 Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Not yet recruiting NCT03167957 Phase 2
27 Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection Completed NCT01067131 Phase 1
28 Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Completed NCT02730494 Phase 1
29 Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463 Completed NCT01812889 Phase 1
30 Will Vaginal Colonization of Lactobacillus Increase Cure Rate After Treatment of Bacterial Vaginosis and Chronic Vulvovaginal Candida Unknown status NCT02295579
31 Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis Completed NCT00803738
32 Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) Completed NCT00895453
33 A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations Completed NCT01039584
34 Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization Completed NCT02888197
35 Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis Completed NCT02203942
36 Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Completed NCT02150655 Early Phase 1
37 Observational Program Neo-Penotran® Forte Completed NCT01335373
38 Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network Completed NCT00503542 Early Phase 1
39 Epidemiological Study in Subjects With Vulvovaginal Candidiases Recruiting NCT03064789
40 Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis Recruiting NCT02859493
41 Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women Recruiting NCT01915251
42 Oral Probiotics for the Treatment and Prevention of Vulvovaginal Infections in Pregnancy - Double-blind, Randomized, Placebo-controlled Study Recruiting NCT02795845
43 Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method Enrolling by invitation NCT02558179
44 Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial Not yet recruiting NCT03075046
45 Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis Terminated NCT02345096
46 Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M® Terminated NCT00915629

Search NIH Clinical Center for Vulvovaginal Candidiasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: candidiasis, vulvovaginal

Genetic Tests for Vulvovaginal Candidiasis

Anatomical Context for Vulvovaginal Candidiasis

MalaCards organs/tissues related to Vulvovaginal Candidiasis:

39
Testes, Skin, Colon, Neutrophil, B Cells

Publications for Vulvovaginal Candidiasis

Articles related to Vulvovaginal Candidiasis:

(show top 50) (show all 369)
id Title Authors Year
1
Comparison of two long-term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study. ( 28066940 )
2017
2
Elevated nitric oxide in recurrent vulvovaginal candidiasis - association to clinical findings. ( 28052314 )
2017
3
ALS1 and ALS3 gene expression and biofilm formation in Candida albicans isolated from vulvovaginal candidiasis. ( 27376044 )
2016
4
Vulvovaginal Candidiasis in Pregnant Women and its Importance for Candida Colonization of Newborns. ( 27552787 )
2016
5
Syngonanthus nitens Bong. (Rhul.)-Loaded Nanostructured System for Vulvovaginal Candidiasis Treatment. ( 27556451 )
2016
6
Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis. ( 27129474 )
2016
7
Microsatellite analysis of genotype distribution patterns of Candida albicans vulvovaginal candidiasis in Nanjing, China and its association with pregnancy, age and clinical presentation. ( 26861467 )
2016
8
Chronic vulvovaginal candidiasis in patients using a levonorgestrel-containing intrauterine device. ( 27957732 )
2016
9
Candida nivariensis as a New Emergent Agent of Vulvovaginal Candidiasis: Description of Cases and Review of Published Studies. ( 26708316 )
2016
10
Highlights Regarding Host Predisposing Factors to Recurrent Vulvovaginal Candidiasis: Chronic Stress and Reduced Antioxidant Capacity. ( 27415762 )
2016
11
Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus. ( 27298383 )
2016
12
Comparing the Recurrence of Vulvovaginal Candidiasis in Patients Undergoing Prophylactic Treatment with Probiotic and Placebo During the 6A Months. ( 27206514 )
2016
13
Antifungal effects of Lavandula binaludensis and Cuminum cyminum essential oils against Candida albicans strains isolated from patients with recurrent vulvovaginal candidiasis. ( 27751723 )
2016
14
The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. ( 27073145 )
2016
15
Management of chronic vulvovaginal candidiasis: a long term retrospective study. ( 27250078 )
2016
16
Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis. ( 27915337 )
2016
17
Genotyping and Persistence of Candida albicans from Pregnant Women with Vulvovaginal Candidiasis. ( 27882525 )
2016
18
A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana. ( 27838642 )
2016
19
The Effects of Ozonated Olive Oil and Clotrimazole Cream for Treatment of Vulvovaginal Candidiasis. ( 27548492 )
2016
20
Quality of life in patients with chronic vulvovaginal candidiasis: A before and after study on the impact of oral fluconazole therapy. ( 27170259 )
2016
21
Candida duobushaemulonii: an emerging rare pathogenic yeast isolated from recurrent vulvovaginal candidiasis in Brazil. ( 27304096 )
2016
22
Phospholipase and Aspartyl Proteinase Activities of Candida Species Causing Vulvovaginal Candidiasis in Patients with Type 2 Diabetes Mellitus. ( 26032358 )
2015
23
Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. ( 25416649 )
2015
24
Vulvovaginal candidiasis in pregnancy. ( 25916994 )
2015
25
Efficacy and safety of a single oral 150A mg dose of fluconazole for the treatment of vulvovaginal candidiasis in Japan. ( 25887336 )
2015
26
Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. ( 26001874 )
2015
27
Isolation of different species of Candida in patients with vulvovaginal candidiasis from sari, iran. ( 26034533 )
2015
28
Detection of phospholipase activity of Candida albicans and non albicans isolated from women of reproductive age with vulvovaginal candidiasis in rural area. ( 25560009 )
2015
29
Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 exhibit strong antifungal effects against vulvovaginal candidiasis-causing Candida glabrata isolates. ( 25688886 )
2015
30
Recurrent vulvovaginal candidiasis. ( 26164695 )
2015
31
Molecular Characterization of Highly Susceptible Candida africana from Vulvovaginal Candidiasis. ( 26183965 )
2015
32
Miconazole Nitrate Vaginal Suppository 1,200 mg versus Oral Fluconazole 150 mg in Treating Severe Vulvovaginal Candidiasis. ( 25720546 )
2015
33
Humoral immune responses to Candida albicans complement receptor 3-related protein in the atopic subjects with vulvovaginal candidiasis. Novel sensitive marker for Candida infection. ( 25673750 )
2015
34
Can intrauterine contraceptive devices lead to VulvoVaginal Candidiasis (VVC) andanemia in Iranian new users? ( 25637424 )
2015
35
The dynamic changes of vaginal microecosystem in patients with recurrent vulvovaginal candidiasis: a retrospective study of 800 patients. ( 26041326 )
2015
36
Transcriptomic Analysis of Vulvovaginal Candidiasis Identifies a Role for the NLRP3 Inflammasome. ( 25900651 )
2015
37
Neutrophil Gelatinase-Associated Lipocalin Concentration in Vaginal Fluid: Relation to Bacterial Vaginosis and Vulvovaginal Candidiasis. ( 25670719 )
2015
38
Case Report Dynamical evaluation of vaginal micro-ecosystem in a Chinese woman with recurrent vulvovaginal candidiasis. ( 25867410 )
2015
39
Treatment of vulvovaginal candidiasis: a review of the literature. ( 25770305 )
2015
40
Molecular identification and antifungal susceptibility of 186 Candida isolates from vulvovaginal candidiasis in southern China. ( 25596116 )
2015
41
Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. ( 26690853 )
2015
42
Vulvovaginal Candidiasis in Aminu Kano Teaching Hospital, North-West Nigeria: Hospital-Based Epidemiological Study. ( 26229716 )
2015
43
Antifungal susceptibility and molecular typing of 115 Candida albicans isolates obtained from vulvovaginal candidiasis patients in 3 Shanghai maternity hospitals. ( 26468549 )
2015
44
A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis. ( 25877666 )
2015
45
Changing trends of vulvovaginal candidiasis. ( 24696557 )
2014
46
Multilocus sequence typing of Candida africana from patients with vulvovaginal candidiasis in New Delhi, India. ( 24697839 )
2014
47
Mannose-binding lectin codon 54 gene polymorphism and vulvovaginal candidiasis: a systematic review and meta-analysis. ( 25143944 )
2014
48
Antifungal susceptibility patterns, in vitro production of virulence factors, and evaluation of diagnostic modalities for the speciation of pathogenic Candida from blood stream infections and vulvovaginal candidiasis. ( 25110589 )
2014
49
Prevalence of Candida nivariensis and Candida bracarensis in vulvovaginal Candidiasis. ( 25118875 )
2014
50
Factors Associated with Symptomatic Vulvovaginal Candidiasis: A Study among Women Attending a Primary Healthcare Clinic in Kwazulu-Natal, South Africa. ( 24971218 )
2014

Variations for Vulvovaginal Candidiasis

Expression for Vulvovaginal Candidiasis

Search GEO for disease gene expression data for Vulvovaginal Candidiasis.

Pathways for Vulvovaginal Candidiasis

GO Terms for Vulvovaginal Candidiasis

Cellular components related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 DEFB1 DEFB4A F2 IL1RN IL2 IL4
2 Golgi lumen GO:0005796 9.33 DEFB1 DEFB4A F2
3 extracellular space GO:0005615 9.17 DEFB1 DEFB4A F2 IL1RN IL2 IL4

Biological processes related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.85 CLEC7A DEFB1 MBL2 NLRP3
2 defense response to bacterium GO:0042742 9.77 DEFB1 DEFB4A MBL2
3 chemotaxis GO:0006935 9.71 DEFB1 DEFB4A IL4
4 positive regulation of protein phosphorylation GO:0001934 9.7 F2 IL2 IL4
5 defense response GO:0006952 9.65 DEFB1 DEFB4A NLRP3
6 positive regulation of B cell proliferation GO:0030890 9.61 IL2 IL4
7 acute-phase response GO:0006953 9.6 F2 MBL2
8 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.58 IL2 IL4
9 B cell activation GO:0042113 9.58 CD79A IL4
10 positive regulation of activated T cell proliferation GO:0042104 9.57 IL2 IL4
11 innate immune response in mucosa GO:0002227 9.56 DEFB1 IL4
12 defense response to protozoan GO:0042832 9.51 CLEC7A IL4
13 defense response to Gram-positive bacterium GO:0050830 9.5 DEFB1 DEFB4A MBL2
14 positive regulation of T cell differentiation GO:0045582 9.49 IL2 IL4
15 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.46 IL2 IL4
16 positive regulation of isotype switching to IgG isotypes GO:0048304 9.43 IL2 IL4
17 negative regulation of acute inflammatory response GO:0002674 9.4 IL4 NLRP3
18 positive regulation of interleukin-13 production GO:0032736 9.37 IL4 NLRP3
19 immune response GO:0006955 9.35 DEFB1 DEFB4A IL1RN IL2 IL4
20 negative regulation of T-helper 17 cell differentiation GO:2000320 9.26 IL2 IL4
21 leukocyte activation involved in immune response GO:0002366 9.16 CLEC7A IL2
22 immune system process GO:0002376 9.02 CD79A CLEC7A IL2 MBL2 NLRP3

Molecular functions related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.43 CLEC7A IL2 MBL2
2 cytokine activity GO:0005125 9.33 IL1RN IL2 IL4
3 growth factor activity GO:0008083 9.13 F2 IL2 IL4
4 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB1 DEFB4A

Sources for Vulvovaginal Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....